The cost of insulin has long been a pain point for diabetic Americans. Now a solution may be in sight.
The House of Representatives passed an insulin cap bill at the end of March 2022. This bill would limit the out-of-pocket cost of insulin for beneficiaries of Medicare Part D as well as some group and individual healthcare plans.
If it passes the Senate, the Affordable Insulin Now Act
will take effect in 2023. Under this bill, patients' monthly insulin costs will be limited to $35 or 25% of the plan's negotiated price, whichever is lower. While the bill could alleviate the elevated cost of insulin, it could come at another price for Americans and healthcare providers.
What Is Insulin and Why Do People Need It?
Insulin production plays a vital role in overall health. As the body digests carbohydrates, it turns them into glucose that releases into the bloodstream. The pancreas produces insulin, a hormone that lets muscle, fat and liver cells absorb glucose to use as energy. Without insulin to signal the cells to absorb the glucose, they can't convert it to energy.
The body's inability to effectively use glucose is called diabetes. This chronic disease is the seventh-highest cause of death
in the U.S. and can lead to several other health issues, including:
- Vision loss
- Heart disease
- Kidney disease
Diabetes is divided into either Type 1 or Type 2 depending on the underlying cause. Type 1 diabetes is the result of an autoimmune disease whereby the immune system attacks the pancreas, making insulin production impossible. With Type 2 diabetes, the pancreas still produces insulin; however, the body doesn't respond to it effectively.
Besides living an active and healthy lifestyle and taking other prescribed medications, taking insulin injections is the primary tool for managing diabetes. Injections of insulin provide the necessary signals to convert glucose into energy and regulate blood glucose levels. People with Type 1 diabetes must use supplemental insulin to manage their body's insulin absorption, and some with Type 2 diabetes may also need injections to manage their blood glucose levels.
Why the Insulin Bill Is Being Proposed
Unfortunately, the exorbitant out-of-pocket cost of insulin can make this necessary treatment prohibitively expensive. Patients with insurance still typically pay a percentage of insulin's list price, which increases as the cost of insulin rises. Patients without insurance must pay retail prices, which can be as high as $1,817.56
per vial of insulin. Many patients need at least two or three vials per month. Soaring prices have motivated many diabetic patients to ration their injections or skip them altogether, actions that risk causing other serious health concerns
The proposed insulin cap bill addresses this financial burden and enables more Americans to afford life-saving insulin injections. The Affordable Insulin Now Act may usher in more talks to curb the rising prices of prescription drugs, which would subsequently lower the out-of-pocket costs.
U.S. House Passes Bill to Cap Insulin
The road to passing the Affordable Insulin Now Act has been long. Here's what happened to get the bill passed:
- The U.S. House passed the Build Back Better Bill: The Build Back Better Bill included an insulin price cap bill in 2021 that limited the out-of-pocket cost of insulin to $35 for a month's supply. Although the House passed the bill on November 19, 2021, it stalled in the Senate.
- A similar bill arose in the U.S. Senate: Democratic senator Raphael Warnock of Georgia introduced the Affordable Insulin Now Act on February 17, 2022. This bill caps the price of insulin products for private health plans at the lesser of $35 or 25% of the negotiated price. For Medicare beneficiaries, the same cap would kick in after a period where the cap remains at $35. The Senate has not yet voted on this bill.
- U.S. House Representatives introduced the Affordable Insulin Now Act: Three Democratic representatives introduced the stand-alone insulin price cap bill in the House in February 2022.
- The U.S. House passed the Affordable Insulin Now Act: On March 31, the House passed the bill. The insulin price cap bill has now moved on to the Senate for a hearing, where it could encounter changes.
Who Benefits from the Insulin Bill
If the bill becomes law, diabetic Americans could pay up to thousands of dollars less for their insulin products every month. The Affordable Insulin Now Act would benefit the following groups in particular:
1. Diabetic Adults and Children
Of the over 37 million U.S. adults with diabetes, approximately 7.4 million
rely on insulin to manage their blood glucose levels. The prevalence of diabetes among children and adolescents has risen dramatically. According to the most recent statistics from the Centers for Disease Control (CDC), about 210,000 children and adolescents in the U.S. live with diabetes.
The gross amount each person spent on insulin increased by $2,841
from 2012 to 2016. The list price per millimeter of insulin also increased by an average of 1.5% annually
from 2016 to 2018. If this trend continues, insulin list prices could continue to skyrocket — according to one projection, gross annual spending on insulin might reach $121.2 billion
The proposed insulin cap bill will make insulin significantly more affordable for these patients.
2. Insulin Manufacturers
A cap on insulin prices may also positively impact insulin manufacturers. Passing a national price cap could turn politicians' focus away from incentivizing insulin manufacturers to lower their prices.
The Affordable Insulin Now Act would also allow more Americans to purchase the insulin they need rather than ration the drug or go without it. This increase in sales would provide insulin manufacturers with more revenue.
Who Might Be Negatively Impacted by Insulin Bill?
Despite the clear benefits for diabetic Americans, the effects of the insulin cap bill may not be all positive. Four main groups could be adversely affected by the proposed insulin cap bill:
- American taxpayers: Because the Affordable Insulin Now Act applies to Medicare Part D, the burden of paying for insulin products for those insured under Medicare falls on the federal government. Since taxpayers fund the government's spending, all taxpaying Americans would ultimately pay for this bill.
- Healthcare providers: While the Affordable Insulin Now Act caps patient cost-sharing, it does not address the list price of insulin products. With patients paying less, the rest of the cost falls on the healthcare providers. Private insurers would have to find ways to pay for their enrollees' insulin products.
- Healthcare enrollees: Facing higher insulin costs, private insurers would likely want to shift those costs back to their enrollees. Healthcare premiums would likely increase for those insured privately.
- The uninsured with diabetes: If the insulin price cap bill reduces the political pressure to address the rising list price of insulin, uninsured patients with diabetes could continue to suffer financially.
Future of Rx Prices Due to Insulin Bill Precedent
Upward trends in insulin list prices may have a broader impact on prescription drug costs.
Some opponents argue that the Affordable Insulin Now Act isn't enough to curb drug list prices. However, advocates say that the bill would set a precedent that might encourage governmental caps on the astronomical cost of prescription drugs. In fact, several senators are working on a bipartisan bill that could bring further changes to prescription drug prices.
Contact The Phia Group, LLC for Healthcare Cost-Containment Services
While it's still unclear whether the Affordable Insulin Now Act will become law, businesses should prepare to handle the increasing cost of insuring their employees.
With The Phia Group, LLC’s cost containment services, your company can keep its healthcare coverage costs low. The Phia Group, LLC is a healthcare-cost containment consultancy firm working to keep the cost of healthcare low for businesses and employees. We offer services like consulting, plan document drafting, subrogation, claim negotiation, and more.